Researchers from multiple universities support psilocybin as a potential depression treatment, with 5.1-5.6 million Americans potentially benefiting if FDA approves.
Researchers from Emory, Wisconsin-Madison, and UC-Berkeley highlight psilocybin's potential in treating depression, possibly benefiting 5.1 to 5.6 million Americans if the FDA approves it. Psilocybin, derived from magic mushrooms, has "breakthrough therapy" status. Meanwhile, Minnesota's task force recommends decriminalizing psilocybin, while the University of Maryland is launching a series to educate healthcare professionals on psychedelic therapies. Ongoing trials aim to assess psilocybin's effectiveness for treatment-resistant depression.
October 07, 2024
6 Articles